1406 (1406) Fair Value & Analysis

Healthcare · Market cap HK$190M

1 1406 1406 · HK

PriceHK$0.3550

Fair ValueHK$0.2300

Upside-35.2%

Quality45/100

Watch 1406 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.1500 – HK$0.2900

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$0.3550 – HK$0.3550 · fair‑value band HK$0.1500 – HK$0.2900 · the HK$0.3550 price screens above the HK$0.2300 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1406 (1406) currently trades at HK$0.3550, while our model-based Fair Value estimate is HK$0.2300 — implying the stock looks roughly 35.2% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1406 generated revenue of HK$177M at a net margin of -42.1%. Revenue declined 14.2% year over year. It earns a return on equity of -35.8%. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$177M

Revenue growth (YoY) -14.2%

Net margin -42.1%

Return on equity -35.8%

Free cash flow −HK$48.4M FY2024

Operating margin -13.4%

More key figures

EPS growth (YoY) -46.3%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

1406 reported revenue of HK$191M in FY2024 versus HK$218M in FY2020, a compound −3.3%/yr. Reported net income was −HK$75.8M in FY2024.

Revenue −3.3%/yr

FY20 HK$218M

FY21 HK$222M

FY22 HK$225M

FY23 HK$214M

FY24 HK$191M

Net income

FY20 HK$26.4M

FY21 HK$35.8M

FY22 HK$13.5M

FY23 −HK$3.2M

FY24 −HK$75.8M

Is 1406 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$412.02	$165.35	-60%
EssilorLuxottica Société anonyme ESLOF	$192.00	$126.51	-34%
HOYA Corporation HOCPY	$178.46	$103.27	-42%
Medline Inc MDLN	$34.71	$30.15	-13%
Becton, Dickinson and Company BDX	$140.71	$104.17	-26%
Alcon Inc ALC	$66.58	$36.99	-44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1406 (1406) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.2300 versus a price of HK$0.3550 — about −35% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1406?

Our model-based fair value for 1406 is HK$0.2300 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.3550.

What is the quality score of 1406?

1406 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1406 (1406)?

1406 reported trailing-twelve-month revenue of about HK$177M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1406?

The net profit margin of 1406 is about -42.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.